News

GlobalGuidance empowers Arkstone to deliver OneChoice recommendations worldwide, transcending language barriers and tailoring treatment options to specific regions through customized drug formularies.

Arkstone is excited to embark on a groundbreaking clinical study in collaboration with Laboratorio Clínico Roe in Peru. This study will explore the transformative capabilities of Arkstone's OneChoice Report, aiming to optimize the judicious use of antibiotic treatments for patients with bacteremia or bloodstream infections.

Building on the success of its molecular lab results OneChoice report, which has already benefited hundreds of thousands of patients and is trusted by thousands of healthcare providers, Arkstone now extends its revolutionary technology to the wider realm of microbiology.

OneChoice now includes interpretations of laboratory data taken via skin scrapings and epidermal samples. This advancement revolutionizes the management of superficial infections with a focus on topical antibiotic treatment.

The partnership between Arkstone Medical Solutions and Dendi represents a significant step forward in providing healthcare providers with the tools and technologies they need to make informed clinical decisions.

The NIH has been collecting lab result isolate data for decades, compiling information about the prevalence of antimicrobial resistance genes in specific organisms.

Now, providers have access to detailed and dynamic renal and hepatic dosing adjustments for any treatment recommendations provided.

Many healthcare providers treating infections in a pregnant patient have difficulty finding the best treatment, while also taking into consideration an antimicrobial that will have the lowest risk to the fetus.